key: cord-0035540-vwmgolwo
authors: Wu, Josephine; Sharaan, Mona; Zhang, David Y.
title: Molecular Virology
date: 2009-12-30
journal: Molecular Genetic Pathology
DOI: 10.1007/978-1-59745-405-6_21
sha: d62e103b920c6a3bc5967ac8cbcaa99c261dff96
doc_id: 35540
cord_uid: vwmgolwo

Traditional viral isolation by cell culture assays and conventional serological methods have been previously used to detect and identify various virus infections

Virus ( 

• Traditional viral isolation by cell culture assays and conventional serological methods have been previou sly used to detect and identify various virus infections • More recently, however, molecular methods, i.e., hybridization and amplification techniques, have been developed that more accurately and rapidly detect viral organisms with improved sensitivity and specificity. Also, these advanced techniques provide laboratories with decreased hands-on time and shorter time to results

• However, the routine implementation of nucleic acid (both DNA and RNA) amplification and hybridization methodologies is associated with limitations, particularly in the clinical laboratory. The se limitations and pitfalls include, but are not limited to:

-Increased cost/test due to expensive instrumentation and reagents -Amplification carryover contamination -Standardization of positive and negative assay controls -Integrated co-amplified internal DNA control to demonstrate absence of polymerase (PCR) inhibitors and amplification -Prevention of false-positive and false-negative report s due to antigenic and pathogen nucleic acid sequence drift and accurate interpretation of data and software analyses

• Specimens: collection of adequate specimen material is important for molecular diagnosis of viruses -Whole blood : 3-5 mL collected in an ethylenediamine tetra acetic acid (EDTA) (lavender top) tube. Store at 4-25°C. Do not freeze -Plasma: Collect 7-10 mL of whole blood in EDTA, acid citrate dextrose (ACD) solution A, or plasma preparation tubes (PPT) (Becton Dickinson, Franklin Lakes, NJ) sterile tube . Store whole blood at room temperature (18-30°C) for no >4 hours . Remove plasma from cells within 4 hours of collection by centrifugation at 1000g for 10-15 minutes. Do not clarify by filtration or further centrifugation. Store plasm a at -60 to -80°C within 30 minutes of separation. Plasma may also be stored at -20°C in non-frost-free freezer for up to n hours if colder freezer is not available. Ship on dry ice for overnight delivery. The minimum volume of specimen is 2 mL of plasma -Urine: first 10-20 mL of void urine collected in a sterile urinalysis container (l5-mL sterile screw-cap tube preferred). Store at 4-25°C for <24 hours or store at -70°C for long term -Bronchial lavage/tracheal aspirate : 1-4 mL, collected in a sterile tube. Store at 4-25°C -Bone marrow : 1-2 ml. , collected in EDTA tube. Store at 4-25°C. Do not freeze -Tissue: approximately 0.5 em tissue block collected in a sterile screw-top container, add small amount of saline to keep it moist. Avoid the use of viral transport media to avoid potential inhibition of PCR. Fresh tissues should be stored at -noc immediately to preserve the nucleic acids. Paraffin-embedded tissue is acceptable. Usually 5-10 sections (5 11m thickness) are sufficient for PCR analysis. The tissue sections must be deparaffinized with xylene before DNA extraction -Fecal : sterile swab (plastic shaft only) or very small fecal sample placed in 1-2 mL sterile saline in a container with tight fitting lid. Do not use viral transport media to avoid potential inhibition of PCR -Swab: sterile swab (plastic shaft only) placed in 1-2 mL sterile saline . Do not use viral transport media to avoid potential inhibition of PCR -Cerebrospinal fluid (CSF): 1-1.5 mL fluid, frozen . Submitted in a sterile , leak-proof tube

• Analytical performance -Analytical sensitivity: to determine the lowest number of targets that can be detected by the assay -Cross-reactivity (specificity): to determine if the assay can produce false-positive results in the presence of high concentration of other similar or unrelated pathogens (bacteria, yeast, and virus) Linearity : to evaluate the log differences from the expected concentration; this difference should be within ±O.l log (or a ratio of observed mean quantitation to expected concentration within 95%) -Quantitative range: the measured concentrations within the linear range with a good reproducibility • Clinical performance -Limit of detection (LOD) : the lowest concentration of target nucleic acids that can be detected (at or above the detection cutoff) in 95% of replicates (usually 10 replicates) -Detection cutoff: the point on the assay quantitation scale such that 95% of negative specimens produce results below this cutoff with 95% confidence -Reproducibility: the reproducibility of the test is usually established by testing three to six sample panels with known concentrations of target in triplicate or quadruplicate. A commercial panel should be used to establish this parameter, if available . Reproducibility is expres ses as percent 535 21-4 coefficient of variation (CV). For quantitative assays, the CVs range from 10 to 50% -Precision: the reproducibility of a test result (e.g., inter-and intra-technologist and inter-and intra-assay) -HIV virus consists of a spherical viral particle encased in a lipid bilayer derived from host cell covered by protruding peg-like structures composed of gp41 and gp120 glycoproteins -The virus core nucleocapsid contains the major capsid protein, p24 ; two copies of genomic RNA, and three viral enzymes (protease, reverse transcriptase [RT] , and integrase

• Viral replication -Entry into the host cell requires binding of the gp 120 molecule on the virus to CD4 molecules on the host cell's surface -Two surface molecules CCR5 and CXCR4, chemokine receptors for~-chemokines and u-chemokines are also required for entry -Once bound, the viral envelope fuses with the cell membrane and the virus's RNA and enzymes enter the cytoplasm -RT allows the single-stranded RNA of the virus to be copied and double-stranded DNA (dsDNA) to be generated -Integrase then facilitates the integration of viral DNA into the cellular chromosome when the cell divides and provides latency enabling the virus to effectively evade host responses -Viral proteins are facilitated by protease and assembled into viral particles using the host cell's protein-making machinery -An HIV-infected cell does not necessarily lyse the cull during replication; in fact many viral particles can bud out of the cell and the cycle begins again

• The gag, pol, and env genes encode for structural proteins for new virus particles. The other six genes tat, rev, nef, vif, vpr, and vpu regulate the synthesis and assembly of viral particles

• The phylogenie analysis of the nucleotide sequences of the env gene has enabled classification of HIV-l into 536 three groups: M (Major), N (non-M), and 0 (outlier).

The group M of HIV-l infection has been classified into nine different genetic subtypes A-K. Presently, group M of HIV-l globally causes 99.6 % of all human infections. Subtype/clade B is the most prevalent in the developed world

• HIV is transmitted via sexual contact, blood (via transfusion, blood products , or contaminated needles) , or passage from mother to child (in utero, during birth, or ingestion of breast milk 

• Lymphocyte count -Quantitation of CD4 cells was the first effective predictor of HIV progres sion -Still used for persons infected with HIV-2 or HIV-l variants not accurately quantitated using viral load assays -The CD4 cell count «200 cells/rum') is important in determining the staging of HIV disease and for indicating the need for prophylaxis against opportunistic pathogens -Measurement and trending of CD4 percentage in addition to absolute count must be performed prior to initiation or adjustment of anti-retroviral (ARV) treatment management decisions -CD4 percentage may widely vary due to concurrent medical conditions, CD4 subsets, and inter-laboratory variation to name a few • Viral culture -Although very specific, single-positive culture must be confirmed with a second specimen 537 

• At least as sensitive as and more specific than screening assays, although they are not as sensitive in the detection of early seroconversion

• Disadvantages: more labor intensive, more prone to subjective interp retation, and more costly than screening assays -Alternative antibody scree ning assay (qualitative) • Food and Drug Admin istration (FDA) has approved assays that test body fluids other than blood to Patient samples drug under artificial conditions in the laboratory. Although phenotyping is a direct measure of resistance it is more complex than genotyping, and therefore slower and more costly to perform -No consensus on genotyping vs phenotyping; however, it is anticipated that genotyping will be used more often because of its greater accessibility, lower cost, and faster turnaround time

• Mechanism of resistance -HIV is a highly polymorphic G virus (quasi-species), which during replication converts RNA to DNA by the action of the viral RT enzyme -The RT enzyme has very little proof reading (correction) capacity, and therefore errors are incorporated into the pro-viral DNA during replication. Over time these errors, at concise drug binding sites, can provide a selection advantage for the virus in the presence of ARV drugs -The resistant virus predominates with a subsequent increase in viral load. However, the extent of such resistance and the implications for choice of therapy can be determined by reading the sequence of the genes encoding the protease and the RT enzymes 

-It is a two-step procedure, which first amplifies the protease and RT regions of the HIV-I genome using RT-PCR -The amplified DNA is then sequenced to yield to the nucleotide profile of the virus using a sequencing gel -Once the sequence has been generated it is compared with the wild-type HIV-I sequence and any difference s that confer drug resistance are highlighted

• ViroSeqTM HIV-I Genotyping System (Celera Diagnostics, Alameda, CA; (distributed by Abbott Laboratories, Abbott Park, IL) -It is a two-step procedure, which first amplifies the protease and RT regions of the HIV-I genome using RT-PCR and cycling sequencing -The amplified DNA is then sequenced to yield to the nucleotide profile of the virus using a capillary electrophoresis -The minimum input of viral RNA to the assay should be 1000 copies/mL when using I mL of plasma to be succes sful in genotyping • Pitfalls of genotyping -Genotypic variants comprising <20-30% of the sample may not be detected as genotyping results reflect the predominate subtype -Interpretation of genotyping results is based on the HIV-I clade B, the most prevalent clade in the developed world . However, other subtypes and recombinants of HIV-I may be undetected -Assessing HIV-I resistance is complicated by the replication kinetics of resistant mutant s. Resist ant mutants are often less fit than wild-type virus and may become undetectable with selective drugs . Nevertheless, these mutants persist in the patient and when the selective drug pressure is reapplied the mutants replicate and a resistant population quickly predominates

• Plasma HIV RNA is a surrogate marker of HIV disease progression that is used to guide and monitor therapy and management

• ARV therapy should be implemented in patients with any of the following clinical findings: symptomatic HIV infection or AIDS-defining condition, CD4 count :::;350 cells/rum? or viral load z I00,000 copies/mL (pregnant mothers: ;::1000 copies/mL)

• The initial highly active ARV therapy goal in the ARV therapy-naive patient should be able to attain a viral load of <50 copies/mL and should include the rational sequencing of ARV agents to achieve the maximum possible viral replication suppression

• In ARV treatment-naive patients or patients who are on a successful treatment regimen, monitoring of viral loads should be measured at baseline, every 2-4 weeks after initiation, and every 3-4 months once maximal suppression is attained, although patients with CD4

counts >500 cells/mm! may require less frequent viral load monitoring • Typically, in patients beginning therapy or in those changing therapy as a result of virologic failure, viral load should be measured 2-4 weeks after therapy initiation. A decrease by at least I log (lO-fold) indicateseffective therapy. Most patients reach the goal of <50 copies/mL within 6 months. An absent or incomplete response of the viral load to ARV therapy should raise concerns about poor patient adherence to therapy and/or viral resistance • If significant increase (threefold increase or more) in viral load without clear explanation, viral load should be repeated to confirm virologic failure • Genotypic-resistancetesting should be performed prior to initiating treatment in ARV therapy-naive patients and in patients with> I000 copies/mL, or non-responsive toARV • Genotypic-resistance testing is not recommended in patients with 500-1000 copies/mL or less and has discontinuedARV therapy for> I year

• HCV is the major cause of non-A, non-B hepatitis (91%) affecting about 3% of the world's population • The most common route of transmission is via blood and blood products, i.e., immunoglobulin, surgery, and intravenous drug abuse, which has significantly reduced with the advent of routine blood screenings. Sexual transmission as well as vertical transmission from mother to infant at a rate of 6% • HCV is a positive-sense, single-stranded RNA virus that representsthe third genus of the family Flaviviridae. The genome encodes for a single open reading frame coding structural (one core and two envelope) proteins as well as a series of non-structural proteins ( Figure 8 ) -5' Untranslated region (NTR): most constant, used for HCV RNA assays, genotyping -Core region: constant, used in some genotype assays, core protein assay, PCR-(restriction fragment length polymorphism [RFLPD, and recombinant immunoblot assay (RIBA) tests -Envelope region: hypervariable region, associated with high rate of mutation in quasi-species -NS2: codes for protease -NS3 region: codes for protease/helicase, RIBA tests target this region -NS4 region: clOOp antigen used in anti-HCV, RIBA tests target this region -NS5a region: codes for interferon response element -NS5b region: codes for RNA polymerase, NS5 antigen used in anti-HCV, and RIBA tests target this region

• HCV consists of a heterogeneous group of genotypes basedon the sequence homology of 5' NTR. Currently, there are six types and over 90 subtypes. Types I, 2, and 3 distributed worldwide, with types la and lb responsible for approximately 60% of infections. Type 4 occursprimarily in the Middle East;type 5 in SouthAfrica, and type 6 in Hong Kong. In the United States, approximately 72% of peopleinfected with hepatitis C havegenotype 1, and most othersare types 2 or 3 (genotypes 4, 5, and 6 are not commonin the United States) • There is littledifference in the mode of transmission or natural history of infection among the differentgenotypes • Cure rates with anti-viral therapy are notablyhigher with genotypes 2 and 3, and the duration of HCV therapyis shorter for these genotypes

• Prior to the isolation of the virus in 1989, hepatic infection with Hepatitis C was previously known as non-A, non-B hepatitis • In the United States, approximately 4 million have been exposed to the virus; 3 million are chronic carriers Acute infection is usually asymptomatic. 25% of patients develop acute hepatitis with jaundice and abnormal liver function ( 

• Blood plasma or serum -Collection of samples in EDTA plasma -Rapid separation of serum or plasma from cells is recommended by centrifugation within 1 hour of collection -Unseparated EDTA plasma is stable at room temperature up to 24 hours after collection -Separated serum or plasma is stable at room temperature for up to 3 days, at refrigerator temperatures for up to 1 week, and frozen at -70°C for years

• Serological studies -Enzyme immunoassay (EIA) • The detection of HCV antibodies is recommended as the initial test for the identification of HCV and is useful for screening at risk populations • EIA is comparatively inexpensive, reproducible, and carries a high sensitivity (99%) and specificity (99%) • EIA can detect antibodies 4-10 weeks after infection • A negative EIA is usually sufficient to exclude the diagnosis of HCV infection in immunocompetent patients • However, the test can be falsely negative in those with immunodeficiencies or end stage renal disease • Once patients seroconvert, they usually remain positive for HCV antibody. Thus, the presen~e of . HCV antibody may reflect remote or recent infection A new "Total HCV core antigen ELISA" (Ortho Diagnostics) for detection and quantification of total core antigen in blood donors • It tests positive for anti-HCV antibodies and for prospective low-risk population screening • Total HCV core antigen ELISA (quantitative, Ortho

Clinical Diagnostics) has sensitivity close to PCR assays in diagnosing acute HCV inf~ctio~s during the window period (before HCV antibodies develop)

• It is also used in monitoring response to anti-viral treatment -RIBA 

After hybridization and washing, streptavidin-labeled alkaline phosphatase is added; followed by incubation with a chromogen, which results in the development of a purple-brown precipitate when there is a match between the probe and the biotinylated PCR product -Hybridization of the amplicon with one or more lines on the strip allows the classification of six major genotypes and their most common subtypes • Invader Assay (Third Wave Technologies, Madison, WI)-applies a new DNA-scanning method, termed cleavase fragment length polymorphism -Relies on the formation of unique secondary structure that results when DNA is allowed to cool following brief heat denaturation and serve as substrates for structure-specific cleavase I enzyme, generating a set of cleavage products -Formation of secondary structures is sensitive to nucleotide sequences -The presence of sequence polymorphisms results in the generation of a unique collection of cleavage products or structural fingerprints -It targets the well-conserved 5' non-coding region ofHCV

• It is important to note that a "genotype bias" is possible for all HCV molecular assays because of the extensive genetic heterogeneity of the virus • False-positive results due to contamination (detected by negative control)

• False-negative results due to amplification inhibition (detected by internal control) or due to a loss of viral DNA during specimen preparation • "Home-brew" or laboratory developed PCR assay are not standardized and variations in sample handling and laboratory methods can affect the sensitivity of the assay

• HCV tests should be used in high-risk patients, such as intravenous drug users, children born to HCV positive mothers, and HIV positive patients. Figure 10 shows the algorithm of HCV testing • Patients suspicious for chronic HCV infection should be tested for HCV antibodies • HCV RNA testing should be performed in:

-Patients with a positive anti-HCV test -Patients considered for anti-viral treatment and require quantitative monitoring -Patients with unexplained liver disease with a negative anti-HCV result and immunocompromised or suspicious for acute HCV infection • HCV genotyping should be determined in HCV infected individuals prior to treatment to guide the duration of therapy and likelihood of response • The treatment of choice is peginterferon plus ribavirin

HBV infection 

• HBV is an enveloped dsDNA hepadnavirus. It is a 47-nm spherical virus with three important polypeptides: hepatitis B surface antigen (HBsAg) is an envelope protein , hepatiti s B core antigen (HBcAg) is a core protein , and hepatitis B e antigen (HBeAg) is an early protein and a non-structural protein coded by core gene. The envelope protein is involved in viral binding and release into susceptible cells . The inner capsid relocates the DNA genome to the cell 's nucleus where viral mRNAs are transcribed

• HBV is a circular, partially dsDNA virus of approximately 3200 nucleotides. This highly compact genome contains four open reading frames encoding the envelope (Pre-SI, Pre-S2, S), core (core, pre-core), polymerase, and X protein ( Figure 11 ) • Although hepatocytes are most susceptible to infection, other cell types may be affected to a lesser extent. The life cycle of HBV begins when it attaches to the cell surface.

In the cytoplasm the DNA is still in the core but then capsid is removed and DNA passes into the nucleus, where it forms a covalently closed circular DNA (cccDNA) • HBV uses the host transcription machinery to replicate its genes and uses RNA polymerase II of the host. The (-) strand of the cccDNA will act as the template for this transcription. After transcription the mRNAs are translated by the host's protein synthesis machinery to form viral proteins in the endoplasmic reticulum. The proteins are then assembled into virions that are secreted • HBV is recognized as endemic in China and other parts of Asia. Over one-third of the world's population has been or is actively infected by HBV • HBV strains are classified into seven genomic groups or genotypes, designated A-G, and based on the nucleotide homology of the surface gene. The predominant HBV genotypes cluster in geographical regions. Genotype A is mainly found in North-Western Europe, North America, and Africa, whereas genotypes Band C have been described in South-Eastern Asian populations. Genotype E and F are seen in East Africa, respectively. Genotype D is most often found in Southern Europe, parts of Central Asia, India, Africa, and the Middle East. Genotype G is a recently determined genotype in France, America, and Germany while genotype H has been reported in patients from Central America Clinical Presentation ( Figure 12) • Transmitted parenterally and sexually by contaminating open cuts or mucous membranes and has a long incubation period (45-120 days)

• Majority of affected patients recover from the illness, characterized by: -Anorexia, nausea, vomiting, headache, fever, abdominal pain, dark urine , and sometimes jaundice -Elevated transaminases, hyperbilirubinemia, and elevated alkaline phosphatase may also occur -Extrahepatic manifestations include arthralagias, arthritis, nephritis , and dermatitis • 10% of patient s continue to carry the virus or markers of the active viral infection >6 months after initial infection -Small percentage may develop chronic-persistent hepatitis with sequence fibrosis and cirrhosis -Incidence of hepatocellular carcinoma is increased with the viral genome found integrated in the cellular DNA in 75% of cases -May be associated with polyarteritis and cryoglobulinemia 

• Viral load testing is used for assessing and monitoring therapy response in HIBV infections ( Figure 15) • In HBV carriers with active liver disease, HBV DNA loads are measured not only to assess patients regarding the need for either interferon-a or lamivudine (a DNA polymerase inhibitor) anti-viral therapy but also to monitor their effectiveness • An increase in HBV viral load is also used as a marker of the emergence of lamivudine-resistant viral mutants '------ • The IC so is defined as the concentration of antiviral agent resulting in a 50% reduction in viral nucleic acid hybridization values (i.e., DNA synthesis) compared with the hybridization values of controls • Disadvantage of DNA hybridization assays is that they require the use of radiolabeled probes • DNA hybridization assays have the advantage over plaque reduction assays of eliminating the variation due to subjective errors resulting from plaque counting by different individuals 556 -Other phenotypic methods: viral production is measured by using IFA-, immunoperoxidase-, ELISA-, or flow cytometry-based methods for detection and quantitation of cells expressing CMV antigens (immediate-early, early, or late)

• Genotypic methods -The mutation of the viral phosphotransferase gene (UL97) coding sequence, which may confer resistance only to ganciclovir -UL97 mutation occurs at three specific sites, within a 700-nucleotide region at the 3' end of the gene, including point mutations within codon 460 and 520 and either point mutations or deletions within the codon range 590-607 

• Specific primers are specifically designed to the EBV viral latent membrane protein 2a (LMP2a) and internal competitor DNA (ssDNA) that is confirmed against a known number of Namalwa cells (B-ce1llymphoma cell line containing two integrated copies of the EBV viral genome per cell)

• Four separate PCR reaction tubes each containing internal competitor DNA (8 copies/ul., 40 copies/ul., 200 copies/ul., or I 000 copies/ul.) are placed in competition with EBV-specific primers for amplification of patient DNA

• PCR ampli cons are examined by electrophoresis through a 2% agaro se gel and visualized using a gel-imaging documentation system . The band densities are quantitatively measured using Bio-Rad's (Hercules, CA) Quantity One software and used to calculate EBV copies

• Detection of LMP gene of EBV viral genome

• EBV is amplified with specific primers in a PCR reaction. The amplicon is detected by fluorescence using a specific pair of hybridization probes • A melting curve analysis is performed after the PCR run to differentiate positive samples from non-EBV species, i.e., other Herpes virus family 559 21-28

• The internal control is added already to the lysed sample before the purification step and co-purified/amplified with the EBV DNA from the specimen in the same PCR reaction (dual color detection)

• LOD for real-time LC PCR is 75-100 copies/mL. The linear range is 100-10 5 copies/mL ELVIS is a method, with no specific manufacturer.

• Technique combines cell culture amplification with HSV-activated reporter genes • The test produces results that are equal to conventional culture

• Most home-brew methods design primers to the thymidine kinase gene. Due to the lack of standardization, variation of the sensitivity and specificity is observed

• Detection and differentiation of HSV type I and type 2 (HSV 1/2)

• HSV 1/2 is amplified with specific primers in a PCR reaction. The amplicon is detected by fluorescence using a specific pair of hybridization probes • A melting curve analysis is performed after the PCR run to differentiate positive samples for HSV I or HSV 2. Melting points for HSV I and HSV 2 are significantly different (HSV-I at 53.9°C, whereas HSV-2 at 67.1 0c), and allows clear determination of the HSV type ( Figure 19 ) • The internal control is added already to the lysed sample before the purification step and copurifiedlamplified with the HSV DNA from the specimen in the same PCR reaction (dual color detection)

• It targets 92-bp region of the HSV type I and type 2 polymerase gene

• It targets the glycoprotein D gene of HSV type I and the glycoprotein G gene of HSV type 2

• The lower LOD (analytical sensitivity) for HSV qualitative PCR is 25 copies/reaction (-1250 copies/mL)

• The sensitivity of PCR : -HSV in skin lesions (sensitivity of 83-100%) and specificity 100% -CSF : sensitivity 70-100%

• HSV was detected more frequently by PCR than by viral culture regardless of whether samples were obtained from HSV lesions, or from genital or oral secretions during a 562 period of sub-clinical shedding. Yield of virus positivity is four times greater by PCR than by culture, and the results are more reliable , especially in settings in which transport or climate may interfere with the yield from viral culture 

• Targets VZV orf 29 gene, and LaD is 500 copies/mL

• 82-bp VZV genome • Analytical sensitivity : 0.8 copy/ul, are recognized as a necessary factor for the development of cervical cancer • The genome HPV virus is circular (Figure 21) . The genome has eight open reading frames that encode ten proteins. The genes for these are divided into an early region that are expressed in the skin's infected basal cells that have yet to differentiate, and a late region with two genes whose protein products exist only in cells after cell differentiation

• The E5 (changes the cellular responses to programmed cell death or apoptosis), E6 (binds to tumor supressor protein , p53), and E7 (binds and inactivates retinoblastoma protein, Rb) proteins are early viral proteins expressed upon infection and cause destabilization of the infected cell and induces replication

• As the cell differentiates, it migrates upward and induces expression of the E1, E2 and E4 genes; EJ and E2 cause viral replication and E4 destabilizes the cytoskeleton and prevent cellular differentiation • In the upper epithelial cell layers the late viral proteins Ll (major capsid protein) and L2 (minor capsid protein) are expressed. They bind the viral DNA and autoassemble, giving rise to the complete virions, ready for a new infection that is released as the keratinocytes desquamate

• The most common mode of transmission is via contact, i.e., sexual or autoinoculation

• HPV is by far the most common sexually transmitted disease. An estimated 80% of sexually active adults have been infected with one or more genital HPV strain s. The vast majority of infected adults experience transient infectivity and are unaware of the condition; however, they may be able to infect others • However, most women infected with high-risk HPV, especially women under 30 years of age, do not develop cervical cancer. Their immune system effectively clears the infection over the course of several months 565 21-34

• Specific factors that determine which HPV infections persist and develop into squamous intraepithelial lesions currently are unknown. Cigarette smoking, ultraviolet radiation, pregnancy, folate deficiency, and immune suppression have been implicated as possible cofactors • Low-risk HPV types (HPV, 6, 11, 42, 43, and 44) produce benign epithelial tumors of the skin and mucous membranes. Infection with certain types of HPV (high risk) can also increase the risk of developing cervical and other cancer types. Conditions associated with HPV:

-Verucca vulgaris (common wart)-associated with HPV-2, HPV-4, and HPV-40. Highly contagious and can spread to other sites of skin or mucous membranes via autoinoculation -Condyloma acuminatum (venereal wart)-associated with HPV-6, HPV-ll, HPV-16, and HPV-18 is considered a sexually transmitted disease with lesions occurring in sites of sexual contact or trauma, i.e., mucous membranes of genitalia, perianal region, oral cavity, and larynx -Flat warts-most commonly found on the face or forehead , and are most common in children and teens -Plantar warts-are found on the soles of the feet -Sub-ungual and periungal warts-warts forming under the fingernail (sub-ungual) and around the fingernail or on the cuticle (periungual) are a subtype of the common skin wart. They may be more difficult to cure than warts in other locations -Butcher's warts--caused by HPV-7 and occurs in people handling meat, poultry, and fish -Focal epithelial hyperplasia (Heck's disease)--caused by HPV-13 (and possibly HPV-32) and commonly occurs in Native American and Inuits. A childhood condition characterized by multiple soft, non-tender flat papules and plaques of the oral mucous membrane -Laryngeal papillomatosis-frequently recur and may require repetitive surgery when interferes with breathing. Rare cases can progress to laryngeal cancer (HPV-30 and HPV-40)

-HIV-associated papillomatosis-HPV-7 and immunocompromised states -Cervical cancer-history of HPV (high-risk types) infection is strongly associated with development of cervical cancer. However, most HPV infections do not progress to cervical cancer. Because the progression of transforming normal cervical into cancerous cells is a slow process, cancer occurs in people who have been infected with HPV for a long time, usually over a decade . -Use tissue sections, liquid-based cytology specimens, and cervical smears -On slide detection of high-and low-risk HPV genotypes 16 probe cocktail for high-risk HPV genotypes 16, 18, 31,33,35,39,51,52,56,58, and 66 Six probe cocktail for low-risk HPV genotypes 6 and II

• Digene Hybrid Capture II (Digene Corporation, Gaithersburg, MD) -Method utilizes a RNA probe mix for the detection of the L I gene of HPY. Assay can identify HR HPV types 16, 18,31,33,35 ,3~45,51,52,5~58,5~and 68. In addition, a kit detecting low-risk virus (6, II, 42,43, and 44) is also available -Signal amplification is based on immunocapture of DNAJRNA hybrids that are immobilized on a 96-well microplate, reacted with alkaline phosphataseconjugated antibodies specific for the RNA:DNA hybrids and detected with a chemiluminescent substrate -Can detect 5000 viral copies per sample, or I pg of HPV DNA per sample • Invader assay (Third Wave Technologies) -This method uses isothermal signal amplification to detect 13 HR HPV types utilizing three probe pools based on phylogenie relatedness. Three probe pools include A5/A6 (51, 56), A7 (18, 39, 45, 59, 68) , and A9 pool (16, 31, 33, 35, 52, 58) -Invader is an isothermal linear signal amplification using structure-specific oligonucleotide cleavage and has been applied to DNA-based genotyping -Uses a pool of biotinylated primers to define a sequence of nucleotides for the Ll region of the HPV genome designed to amplify HPV DNA from 37 HPV genotypes, including 13 high-risk genotypes (16, 18, 31, 33, 35, 39,45, 51, 52, 56, 58, 59, and 68) -B-globulin gene is concurrently isolated and ensures adequacy of cellularity, extraction, and amplification for each processed sample

• Overall, the sensitivity for cytology for detecting high grade squamous intraepitheliallesion (HGSIL) ranges from 50-70% and specificity 86-98%

• Overall, the sensitivity of HPV DNA test for detecting HGSIL is about 80-98% and specificity 64-95%

• However, the sensitivity and specificity is influenced by the age and prevalence ( 

• It targets a conserved region of the matrix , and NA genes of influenza A and B

Sensitivity and Specificity (Table 11) • Sensitivity of DFA methodology is dependent upon adequacy of the specimen , i.e., >20 cells . Otherwise, 

• Due to the length of time required to perform viral culture, the assay has poor efficacy as results are obtained much after the patient has left the office or well past the time when drug therapy could be effective

• Development of PCR-based assays must always consider antigenic drift and random mutations due to viral evolution that may result in false-negatives

• Because of cost, availability, and sensitivity issues, diagnosis of influenza is often based on clinical criteria and presentation

• RT-PCR and TaqMan assays provide a rapid and specific diagnosis of influenza to allow for early therapeutic intervention and prophylactic treatment in high-risk patients, i.e., geriatric care facility

• Molecular diagnosis will playa large role in epidemiologic surveillance, vaccine strain selection, and surveillance of emergent novel influenza viruses, i.e., the Hong Kong H5N I outbreak with sequence analysis

• Influenza viruses that infect birds are called avian influenza viruses. Only influenza A viruses and subtypes infect birds • There are substantial genetic differences between the subtypes that typically infect both people and birds. -EraGen's platform increases size of the genetic "alphabet" from the two DNA base pairs to six pairs with the development of eight new synthetic bases -It is a new, multiplexed real-time PCR platform -Only standard PCR primers need to be designed . Since reporters are placed directly onto the primers and not on probes -It targets nucleocapsid (nuc) or polymerase (pol) gene

• Sensitivity of commercial assays ranged from 36% to 80%; and specificity ranged from 80% to 100%

• The absolute sensitivity of the RT-PCR assays ranged from 10 to 100 genome equivalents per reaction

• When present, SARS antibodies can be detected in serum at any point during the course of the disease . However, most patients do not seroconvert until after the second week, highlighting the importance of an RT-PCR assay for early diagnosis of the virus • Positive results must be confirmed by repeat testing using an aliquot of the original specimen and/or another laboratory before reporting. Alternatively, testing of a second gene region may be helpful. Furthermore, testing of one sample from a single source does not rule out the presence of SARSassociated coronavirus (Figure 27) • Real-time RT-PCR-ABI Prism (Applied Biosystems, Foster City, CA)

-Improved speed and accuracy using TaqMan assay platform Targets conserve sequences of the 5' NTR and VP 1 and 2 (capsid protein) . The 5' NTR is the most highly conserved region and is involved in viral protein translation An enterovirus real-time TaqMan PCR analysis of serum or plasma may be a good alternative for the enterovirus culture of feces, particularly in neonates with sepsis

• Targets conserve sequences of the 5' untranslated region (NTR)

• It detects a I 15-bp region of the 5' UTR Nucleic Acid Sequence-Based Assay 

• NASBA-ECL and NASBA-beacon were similar in sensitivity, (100 %) and ( 

• The BK (BKV) and IC viruses (lCV) are small, nonenveloped , and closed circular dsDNA virus and belong to human polyomaviruses, members of the Papovaviridae family • They were first isolatedin 1971 and named IC and BK after the initials of the patients in which they were first discovered. ICV was isolated from the brain tissue of a patient with progressive multi-focal leukoencephalopathy (PML); BKV was isolated from the urine of a renal transplant patient who developed ureteral stenosis post-operatively • BKV and ICV share 75% homology at the level of nucleot ide sequence. Each is 70% homologous to SV40

• The two are not cross-reactive serologically and serologic tests for antibodies are able to distingui sh between BKV and ICV

• >70 % of the adult population has antibodies to BKV and ICV, with primary infections typically occurring in childhood

• After an initial infection, polyomaviruses establish latency in various tissues . The primary sites of latency are uroepithelial cells for BKV and B-Iymphocytes and renal tissue for ICV. Additional sites of latency for both viruses include the ureters, brain , and spleen

Clinical Presentation 

• Competition between ICV and BKV due to sensitivity may lead to false-negative PCR result SUGGESTED READING

Resistance of human cytomegalovirus to antiviral drugs

Quantitative analyses of cytomegalovirus genome in aqueous humor of patients with cytomegalovirus retinitis

Hepatocellular carcinoma: molecular interactions between hepatitis C virus and p53 in hepatocarcinogenesis

Quantitation of cytomegalovirus: methodologic aspects and clinical application s

Cytomegalovirus (CMV) viremia detected by polymerase chain reaction identifies a group of HIV-positive patients at high risk of CMV disease

Interrelationships among quantity of human cytomegaloviru s (HCMV) DNA in blood, donor-recipient serostatus, and administration of methylprednisolone as risk factors for

HCMVdisease following liver transplantation

Responseof the clinical microbiology laboratory to emerging (new) and reemerging infectiousdiseases

Hepatitis C virusRNA tests: performance attributes and theirimpact on clinical utility

Quantityof cytomegalovirus viruria is a major risk factor for cytomegalovirus disease after renal transplantation

Macrophages and cytokinesin the early defense against herpes simplex virus

Real-Time PCR in clinical microbiology: applications for routine laboratorytesting

Quantification of human cytomegalovirus DNA by real-time PCR. 1

Longitudinal fluctuation in cytomegalovirus load in bone marrowtransplantpatients: relationship between peak virus load, donor/recipient serostatus, acute GVHD and CMV disease

Development and evaluation of a real-timequantitative PCR for the detection of humancytomegalovirus

Rapid detectionand quantification of CMV DNA in urine using LightCycler-based real-time PCR

Monitoringof renal allograft recipientsby quantitationof human cytomegalovirus genomes in peripheral blood leukocytes

Comparisonof the NucliSens basic kit (nucleicacid sequence-based amplification) and the ArgeneBiosoft enterovirus consensusreverse transcription-PCR assays for rapid detectionof enterovirus RNA in clinical specimens

Real-Tune nucleic acid sequence-based amplification usingmolecular beacons for detection of enterovirus RNA in clinical specimens

Real-time automated PCRfor early diagnosis and monitoring of cytomegalovirus infection afterbonemarrow transplantation

Moleculardiagnosis of severe acute respiratorysyndrome

Enhancedclinical utility of the NucliSensEasyQ RSV A+B Assay for rapid detectionof respiratory 580 Molecular Genetic Pathology syntitial virus in clinical samples

New commercially available PCR and microplate hybridization assay for detection and differentiation of human polyomaviruses JC and BK in cerebrospinal fluid, serum, and urine samples

Epstein-Barr virus infection: basis of malignancy and potentialfor therapy

Detection of humancytomegalovirus DNA by real-timequantitative PCR.1

Oral and Maxillofacial Pathology

Enterovirus moleculardetection and typing

Moleculartesting in the diagnosisand management of hepatitisC virus infection

Risk for retinitis in patients with AIDS can be assessedby quantitation of threshold levelsof cytomegalovirus DNAburden in blood

Update on adenovirus and its vectors

Utility of urine and leukocyte cultures and plasma DNApolymerase chain reaction for identification of AIDS patients at risk for developing humancytomegalovirus disease

Plasma cytomegalovirus (CMV) DNA load predictsCMV disease and survival in AIDS patients

Diagnosisof influenzavirus: coming to grips with the molecularera

Quantitative analysisof cytomegalovirus load using a real-timePCR assay

Correlation of cytomegalovirus DNA levels with responseto antiviral therapy in cardiac and renal allograft recipients

Detectionand differentiation of human polyomaviruses JC and BK by LightCycler PCR

Late cytomegalovirus disease in marrow transplantation is predictedby virus load in plasma

New nucleic acid diagnostic tests in viral hepatitis

• Detection of the virus by PCR may be indicative of an active infection. Therefore, the identification of viral DNA may warrant the institution of anti-viral therapies and/or a decrease of immunosuppressive therapies • Determination of viral DNA presence or concentration in transplant patients is useful in establishing the cause of allograft rejection. Viral load may also be useful in immunocompromised patients• BKV nephropathy is associated with BK viremia of >5000 copies/mL (plasma) and BK viremia>10 7 copies/mL and is seen in approximately 8% of kidney transplant recipients• Though latency is typically associated with the absence of viremia, low levels «2000 copies/mL plasma) are seen in some asymptomatic individuals -ICV is difficult to culture -The most sensitive cell type for ICV is primary human fetal glial cells, which is not an easy reagent to acquire -BKV will grow in common cell lines, such as human diploid fibroblasts, but several days and weeks are required before CPE is evident• Serologic studies -Hemagglutination-inhibition or ELISA methods can measure titers of antibodies to ICV and BKV -Serological tests of blood and CSF for anti-ICV and BKV antibodies are not useful in the diagnosis of PML and immunosupressed individuals because antibodies to ICV and BKV are common and many patients with PML or immunosupressed patients fail to develop a significant rise in anti-viral antibody titers in serum or CSF

•